{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"143-809-816-479-547","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"143-809-816-479-547"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11648,"type":"PATENT","title":"Tohoku University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":12827,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8314,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:tohoku uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 10000
Search Applicants and Owners separately:tohoku uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 10000
(a) preparing and identifying a peptide fragment by fragmenting a separated plasma membrane protein target molecule to be quantified; and selecting a subject peptide for quantification that can be ionized by ESI method based on criteria consisting of at least (1) and (2) set forth below and based on selective criteria (3) to (11) set forth below, each selective criterion having a score value, wherein a peptide is preferentially selected as the subject peptide for quantification if it meets at least criteria (1) and (2) and if it has a high total score value based on said score values of selective criteria (3) to (11):\n\n(1) the peptide is obtained by fragmenting with a protease selected from trypsin, endoproteinase, and pepsin;\n(2) the peptide sequence is specific to the target molecule;\n(3) where it is a peptide wherein the content of hydrophobic amino acids is 80% or less and wherein not more than 10 hydrophobic amino acids are consecutive, where hydrophobic amino acids are selected from tryptophan, tyrosine, valine, leucine, isoleucine and phenylalanine, score 2 is given;\n(4) where it is a peptide wherein the number of amino acid residues is 4 to 30, score 3 is given;\n(5) where it is a peptide that does not contain the sequence of asparagine-X-serine, asparagine-X-threonine, or asparagine-X-cysteine as specific amino acid sequence conditions, wherein X represents an amino acids other than proline, score 2 is given;\n(6) where, except when a post-translational modified protein is being quantified, it is a peptide that does not contain a post-translation modified site, score 3 is given;\n(7) where it is a peptide that does not contain a single nucleotide polymorphism (SNP) site, score 4 is given;\n(8) where it is a peptide wherein a cleavage site of the protease is not arginine-arginine, arginine-lysine, lysine-arginine, or lysine-lysine, score 5 is given;\n(9) where it is a peptide that does not contain a transmembrane domain when the protein structure is determined or estimated, score 2 is given; and\n(10) where it is a peptide that does not contain methionine or cysteine, score 3 is given; and\n(11) where it is a peptide that does not contain tryptophan or glutamic acid, score 1 is given;\n
(b) preparing a stable-isotope labeled peptide having the same sequence as the subject peptide for quantification and labeled with a stable-isotope by a peptide synthesis method;\n
(c) preparing a calibration curve by using the subject peptide for quantification and the stable-isotope labeled peptide and performing mass spectrometry using LC/MS/MS for each predetermined concentration level;\n
(d) performing mass spectrometry by using LC/MS/MS by adding the stable-isotope labeled peptide to the peptide fragment obtained by fragmenting the plasma membrane protein to be quantified and calculating the mass spectrum area ratio of the peptide fragment to the stable-isotope labeled peptide; and\n
(e) calculating a quantitative level of the plasma membrane protein from the mass spectrum area ratio by using the calibration curve."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the hydrophobic amino acid content in selective criterion (3) is 50% or less, and the number of amino acid residues in selective criterion (4) is 8 to 12."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, further comprising an additional criterion (12):\n
(12) the same amino acid sequence of the peptide is found in plural animal species;\n
wherein the peptide is preferentially selected as the subject peptide for quantification if it meets at least criteria (1), (2) and (12) and if it has a high total score value based on said score values of selective criteria (3) to (11)."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein plural specific measurement channels are prepared by combining parent ion (m/z) and peptide fragment ion (m/z) of candidate peptides selected according to the criteria for selecting subject peptide for quantification, and measured."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 4, wherein the plural specific channels are prepared for plural candidate peptides of the same protein and for a candidate peptide for plural proteins, and measured at the same time."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the stable-isotope labeled peptide is labeled with an amino acid containing any one of 15N, 13C, 18O, or 2H."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein a source of plasma membrane protein is a tissue sample."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is one or more proteins selected from the group consisting of human ABCA1, human ABCA2, human ABCA3, human ABCA4, human ABCA5, human ABCA6, human ABCA7, human ABCA8, human ABCA9, human ABCA10, human ABCA12, human ABCA13, human ABCB1, human ABCB4, human ABCB5, human ABCB11, human ABCC1, human ABCC2, human ABCC3, human ABCC4, human ABCC5, human ABCC6, human ABCC7, human ABCC8, human ABCC9, human ABCC10, human ABCC11, human ABCC12, human ABCC13, human ABCG1, human ABCG2, human ABCG4, human ABCG5, human ABCG8, and human P-glycoprotein."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is one or more proteins selected from the group consisting of human SLC10A1, human SLC10A2, human SLC15A1, human SLC15A2, human SLC16A1, human SLC16A7, human SLC19A1, human SLC19A2, human SLC19A3, human SLC21A1, human SLC21A10, human SLC21A11, human SLC21A12, human SLC21A13, human SLC21A14, human SLC21A15, human SLC21A19, human SLC21A2, human SLC21A20, human SLC21A3, human SLC21A4, human SLC21A5, human SLC21A6, human SLC21A7, human SLC21A8, human SLC21A9, human SLC22A1, human SLC22A10, human SLC22A11, human SLC22A12, human SLC22A13, human SLC22A14, human SLC22A15, human SLC22A16, human SLC22A17, human SLC22A18, human SLC22A2, human SLC22A3, human SLC22A4, human SLC22A5, human SLC22A6, human SLC22A7, human SLC22A8, human SLC22A9, human SLC23A1, human SLC23A2, human SLC28A1, human SLC28A2, human SLC28A3, human SLC29A1, human SLC29A2, human SLC29A3, human SLC29A4, human SLC31A1, human SLC3A2, human SLC43A1, human SLC43A2, human SLC43A3, human SLC7A5, human SLC7A6, and human SLC7A8."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is one or more proteins selected from the group consisting of human SLC10A3, human SLC10A4, human SLC10A5, human SLC10A6, human SLC11A1, human SLC11A2, human SLC12A1, human SLC12A2, human SLC12A3, human SLC12A4, human SLC12A5, human SLC12A6, human SLC12A7, human SLC12A8, human SLC12A9, human SLC13A1, human SLC13A2, human SLC13A3, human SLC13A4, human SLC13A5, human SLC14A1, human SLC14A2, human SLC15A3, human SLC15A4, human SLC16A10, human SLC16A11, human SLC16A1, human SLC16A13, human SLC16A14, human SLC16A2, human SLC16A3, human SLC16A4, human SLC16A5, human SLC16A6, human SLC16A8, human SLC16A9, human SLC17A1, human SLC17A2, human SLC17A3, human SLC17A4, human SLC17A5, human SLC17A6, human SLC17A7, human SLC17A8, human SLC18A1, human SLC18A2, human SLC18A3, human SLC1A1, human SLC1A2, human SLC1A3, human SLC1A4, human SLC1A5, human SLC1A6, human SLC1A7, human SLC20A1, human SLC20A2, human SLC23A3, human SLC24A1, human SLC24A2, human SLC24A3, human SLC24A4, human SLC24A5, human SLC24A6, human SLC25A1, human SLC25A10, human SLC25A11, human SLC25A12, human SLC25A13, human SLC25A14, human SLC25A15, human SLC25A16, human SLC25A17, human SLC25A18, human SLC25A19, human SLC25A2, human SLC25A20, human SLC25A21, human SLC25A22, human SLC25A23, human SLC25A24, human SLC25A25, human SLC25A26, human SLC25A27, human SLC25A28, human SLC25A29, human SLC25A3, human SLC25A30, human SLC25A31, human SLC25A32, human SLC25A33, human SLC25A34, human SLC25A35, human SLC25A36, human SLC25A37, human SLC25A4, human SLC25A5, human SLC25A6, human SLC25A7, human SLC25A8, human SLC25A9, human SLC26A1, human SLC26A10, human SLC26A11, human SLC26A2, human SLC26A3, human SLC26A4, human SLC26A5, human SLC26A6, human SLC26A7, human SLC26A8, human SLC26A9, human SLC27A1, human SLC27A2, human SLC27A3, human SLC27A4, human SLC27A5, human SLC27A6, human SLC2A1, human SLC2A10, human SLC2A11, human SLC2A12, human SLC2A13, human SLC2A14, human SLC2A2, human SLC2A3, human SLC2A4, human SLC2A5, human SLC2A6, human SLC2A7, human SLC2A8, human SLC2A9, human SLC30A1, human SLC30A10, human SLC30A11, human SLC30A2, human SLC30A3, human SLC30A4, human SLC30A5, human SLC30A6, human SLC30A7, human SLC30A8, human SLC30A9, human SLC31A2, human SLC32A1, human SLC33A1, human SLC34A1, human SLC34A2, human SLC34A3, human SLC35B1, human SLC35B2, human SLC35B3, human SLC35B4, human SLC35C1, human SLC35C2, human SLC35D1, human SLC35D2, human SLC35D3, human SLC36A1, human SLC36A2, human SLC36A3, human SLC36A4, human SLC37A1, human SLC37A2, human SLC37A3, human SLC37A4, human SLC38A1, human SLC38A2, human SLC38A3, human SLC38A4, human SLC38A5, human SLC38A6, human SLC3A1, human SLC40A1, human SLC41A1, human SLC41A2, human SLC41A3, human SLC44A1, human SLC44A2, human SLC44A3, human SLC44A4, human SLC44A5, human SLC45A1, human SLC45A2, human SLC45A3, human SLC45A4, human SLC4A1, human SLC4A10, human SLC4A11, human SLC4A2, human SLC4A3, human SLC4A4, human SLC4A5, human SLC4A7, human SLC4A8, human SLC4A9, human SLC5A1, human SLC5A11, human SLC5A12, human SLC5A2, human SLC5A3, human SLC5A4, human SLC5A5, human SLC5A9, human SLC6A1, human SLC6A10, human SLC6A11, human SLC6A12, human SLC6A13, human SLC6A14, human SLC6A15, human SLC6A16, human SLC6A17, human SLC6A18, human SLC6A19, human SLC6A2, human SLC6A20, human SLC6A3, human SLC6A4, human SLC6A5, human SLC6A6, human SLC6A7, human SLC6A8, human SLC6A9, human SLC7A1, human SLC7A10, human SLC7A11, human SLC7A13, human SLC7A14, human SLC7A2, human SLC7A3, human SLC7A4, human SLC7A7, human SLC7A9, human SLC8A1, human SLC8A2, human SLC8A3, human SLC9A1, human SLC9A2, human SLC9A3, human SLC9A4, human SLC9A5, human SLC9A6, human SLC9A7, human SLC9A8, and human SLC9A9."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is one or more proteins selected the group consisting from human SLC35A1, human SLC35A2, human SLC35A3, human SLC35A4, human SLC35A5, human SLC35E1, human SLC35E2, human SLC35E3, human SLC35E4, human SLC35F1, human SLC35F2, human SLC35F3, human SLC35F5, human SLC39A1, human SLC39A10, human SLC39A11, human SLC39A12, human SLC39A13, human SLC39A14, human SLC39A2, human SLC39A3, human SLC39A4, human SLC39A5, human SLC39A6, human SLC39A7, human SLC39A8, human SLC39A9, human SLC42A1, human SLC42A2, and human SLC42A3."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is human MATE1 or human MATE2."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method for quantifying a plasma membrane protein according to claim 1, wherein the plasma membrane protein is one or more proteins selected from the group consisting of human ABCA1, human ABCA2, human ABCA3, human ABCA4, human ABCA5, human ABCA6, human ABCA7, human ABCA8, human ABCA9, human ABCA10, human ABCA12, human ABCA13, human ABCB1, human ABCB4, human ABCB5, human ABCB11, human ABCC1, human ABCC2, human ABCC3, human ABCC4, human ABCC5, human ABCC6, human ABCC10, human ABCC11, human ABCC12, human ABCC13, human ABCG1, human ABCG2, human ABCG4, human ABCG5, human ABCG8, human MATE1, human MATE2, human SLC3A2, human SLC7A5, human SLC7A6, human SLC10A1, human SLC10A2, human SLC15A1, human SLC15A2, human SLC16A1, human SLC16A7, human SLC19A1, human SLC21A2, human SLC21A3, human SLC21A4, human SLC21A5, human SLC21A6, human SLC21A7, human SLC21A8, human SLC21A9, human SLC21A11, human SLC21A12, human SLC21A13, human SLC21A14, human SLC21A15, human SLC21A19, human SLC21A20, human SLC22A1, human SLC22A2, human SLC22A3, human SLC22A4, human SLC22A5, human SLC22A6, human SLC22A7, human SLC22A8, human SLC22A9, human SLC22A10, human SLC22A11, human SLC22A12, human SLC22A13, human SLC22A14, human SLC22A15, human SLC22A16, human SLC22A17, human SLC23A1, human SLC23A2, human SLC28A1, human SLC28A2, human SLC28A3, human SLC29A1, human SLC29A2, and human SLC31A1."],"number":13,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}